Biopharmx CORPORATION. Common (NYSEAMERICAN:BPMX)’s Stock Is Buy After Less Market Selling

May 18, 2018 - By Karen Cook

BioPharmX Corporation (NYSEAMERICAN:BPMX) Logo

The stock of Biopharmx CORPORATION. Common (NYSEAMERICAN:BPMX) registered a decrease of 4.1% in short interest. BPMX’s total short interest was 11.01 million shares in May as published by FINRA. Its down 4.1% from 11.48M shares, reported previously. With 4.50M shares average volume, it will take short sellers 2 days to cover their BPMX’s short positions.

The stock decreased 0.47% or $0.0009 during the last trading session, reaching $0.1896. About 237,111 shares traded. BioPharmX Corporation (NYSEAMERICAN:BPMX) has declined 50.58% since May 18, 2017 and is downtrending. It has underperformed by 62.13% the S&P500.

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter products that address dermatology and womenÂ’s health markets. The company has market cap of $36.31 million. The firm offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). It currently has negative earnings. The Company’s clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: